CARDIOPROGRESS
Foundation for the advancement of cardiology

Knowledge, observation, action

ESC Congress 2022 Barcelona & Online. Conference news

Evolocumab Benefits Accrue With Longer Follow-up: FOURIER OLE

https://www.medscape.com/viewarticle/979950

Factor XIa Inhibitor Encouraging in Phase 2 MI, Stroke Studies

https://www.medscape.com/viewarticle/979942

No Benefit of Routine Stress Test POST-PCI in High-Risk Patients

https://www.medscape.com/viewarticle/979866

Artificial Intelligence Poised to Change CV Risk Prevention

https://www.medscape.com/viewarticle/979865

Albuminuria Linked to Higher CVD Risk in Diabetes

https://www.medscape.com/viewarticle/979864

COVID-19 Vaccine Safe in Patients With Heart Failure

https://www.medscape.com/viewarticle/979863

Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease

https://www.medscape.com/viewarticle/979861

AXIOMATIC-SSP: Cautious Optimism on Factor XI Inhibitor in Stroke

https://www.medscape.com/viewarticle/979860

ALL-HEART: No Benefit of Allopurinol in Ischemic Heart Disease

https://www.medscape.com/viewarticle/979859

Artificial Intelligence Beats Sonographers for Echo Accuracy

https://www.medscape.com/viewarticle/979857

Dapagliflozin's HFpEF Benefit Recasts HF Treatment: DELIVER

https://www.medscape.com/viewarticle/979855

DANCAVAS Hints at Benefit from Comprehensive CV Screening

https://www.medscape.com/viewarticle/979854

PCI Fails to Beat OMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

https://www.medscape.com/viewarticle/979853

Vintage Drug Atop Loop Diuretics Boosts ADHF Decongestion: ADVOR

https://www.medscape.com/viewarticle/979851

An Hour of Walking Per Week May Boost Longevity in Elderly

https://www.medscape.com/viewarticle/979831

Sacubitril/Valsartan Shows Cognitive Safety in Heart Failure

https://www.medscape.com/viewarticle/979826

Cannabis for Pain Linked to Slight Risk for Arrhythmia

https://www.medscape.com/viewarticle/979824

Secondary CV Prevention Benefit From Polypill Shown

https://www.medscape.com/viewarticle/979821

TIME: CV Events Similar With Evening or Morning Dose of BP Meds

https://www.medscape.com/viewarticle/979812

NSAIDs Linked to Heart Failure Risk in Diabetes

https://www.medscape.com/viewarticle/979762

Barcelona Beckons for First Hybrid ESC Congress

https://www.medscape.com/viewarticle/979477

Mandrola Previews His Top 5 Trials from ESC 2022

https://www.medscape.com/viewarticle/979560#vp_1

Scientific news

Time-Restricted Eating May Help Adults With Metabolic Syndrome Improve Several Health Markers According to a randomized controlled trial, adults with metabolic syndrome and elevated blood sugar levels who eat for a limited time may experience minor improvements in several indicators, including A1c levels, weight, and body fat.

Impact of multiple obesity metrics on hypertensive disorders of pregnancy: a meta-analysis and Mendelian randomisation study This study demonstrates that various obesity measures are causally linked to increased HDP risk and highlights the mediating role of triglycerides. These findings could inform clinical practices and public health strategies aimed at reducing HDP through targeted obesity and triglyceride management.

Optimal treatment of symptomatic patients with low-gradient severe Aortic valve Stenosis and preserved left ventricular ejection fraction (ROTAS trial) The best management of symptomatic patients with low-gradient (LG) severe aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF) has not been established.

Cardiovascular safety of vitamin B3 administration Scientists recently reported associations between serum levels of the terminal niacin metabolites N1-methyl-2-pyridone-5-carboxamide (2PY) and N1-methyl-4-pyridone-3-carboxamide (4PY) with an increased 3-year incident risk of major adverse cardiovascular events.

Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function Semaglutide (Wegovy) prevents major cardiac events including death in adults with overweight/obesity and cardiovascular disease (CVD), both with and without impaired kidney function, a subgroup analysis of the Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) trial shows.

Partners

Video resource

Channel "Cardioprogress"

Follow us